TDP-43, the transactive response (TAR) DNA binding protein, is a transcription factor found in most human tissues. It is a recently identified target of growing interest for neuroOrphan indications such as frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). It also plays an important role in other significant neurodegenerative indications such as Alzheimer’s disease (AD).
The collaboration is aimed at deciphering the governing principles of how pathological forms of TDP-43 spread from neuron to neuron, leading to a better understanding of the TDP-43 pathologies in order to support the Company’s mission to develop novel therapeutic and diagnostic approaches against FTLD and other neurodegenerative diseases.
For further information, please contact:
AC Immune Investor Relations
Phone: +1 646 876 5538
Phone: +1 617 792 3937
AC Immune Global Communication Lead
Phone: +44 7932 053829
|European Investors & Media
Phone: +41 79 367 6254
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA